Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Leukemia Clinical Trial

Official title:

A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00118196
• Other study ID #: CDR0000433313
• Secondary ID: MUSC-MDS2773MUSC
• Status: Terminated
• Phase: Phase 2
• Start date: April 2005
• Est. completion date: August 11, 2006

Study information

• Verified date: May 2018
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as azacitidine and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving azacitidine together with arsenic trioxide works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia.

Description:

OBJECTIVES:

Primary

• Determine the response rate in patients with myelodysplastic syndromes or chronic myelomonocytic leukemia treated with azacitidine and arsenic trioxide.

Secondary

• Determine time to treatment failure in patients treated with this regimen.

• Determine the tolerability and toxicity of this regimen in these patients.

• Determine progression-free survival of patients treated with this regimen.

OUTLINE: This a multicenter, non-randomized, open-label, study.

Patients receive azacitidine subcutaneously once daily on days 1-5 and arsenic trioxide IV over 1-2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are evaluated for response on day 113 (week 17). Patients with disease progression or no response are removed from the study. Patients achieving a complete response (CR) receive 2 additional courses of therapy and then undergo observation. Patients achieving a partial response receive 2 additional courses of therapy and then receive arsenic trioxide alone twice weekly in the absence of CR, disease progression, or unacceptable toxicity.

After completion of study treatment, patients are followed every 2 months for at least 1 year.

PROJECTED ACCRUAL: A total of 19-41 patients will be accrued for this study within 18 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: August 11, 2006
• Est. primary completion date: August 11, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of myelodysplastic syndrome or chronic myelomonocytic leukemia

• International Prognostic Scoring System (IPSS) score = intermediate-1

• Low IPSS score allowed provided patient meets = 1 of the following criteria:

• Platelet count = 50,000/mm^3

• Required platelet or packed red cell transfusions within the past 4 weeks

• Neutropenic (i.e., absolute neutrophil count < 1,000/mm^3) AND has infections requiring antibiotic treatment

• No prior leukemia or refractory anemia with excess blasts in transformation

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• More than 12 weeks

Hematopoietic

• See Disease Characteristics

Hepatic

• Bilirubin = 1.5 times upper limit of normal (ULN)

• AST and ALT = 2.5 times ULN

Renal

• Creatinine = 1.5 times ULN

Cardiovascular

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• Baseline QTc < 500 msec

• QTc interval < 460 msec with potassium > 4.0 mEq/L and magnesium > 1.8 mg/L

Immunologic

• No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs

• No ongoing or active infection

• HIV negative

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 6 months after study participation

• No psychiatric illness or social situation that would preclude study compliance

• No other uncontrolled illness

• No other malignancy within the past 12 months

PRIOR CONCURRENT THERAPY:

Biologic therapy

• More than 4 weeks since prior administration of any of the following:

• Interferon

• Filgrastim (G-CSF), sargramostim (GM-CSF), epoetin alfa, or other hematopoietic cytokines

• Thalidomide or thalidomide analogs

• No concurrent epoetin alfa

Chemotherapy

• More than 4 weeks since prior chemotherapy

• No prior arsenic trioxide or azacitidine

• No other concurrent chemotherapy

Endocrine therapy

• More than 4 weeks since prior steroids

• No concurrent androgenic steroids

• Concurrent steroids for adrenal failure or as prophylaxis for nausea allowed

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• More than 4 weeks since prior retinoids

• No other concurrent investigational agents

• No other concurrent anticancer therapy

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• arsenic trioxide

• azacitidine

Locations

Country	Name	City	State
United States	Hollings Cancer Center at Medical University of South Carolina	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate (overall and confirmed) as measured by International Working Group (IWG) standardized criteria for MDS at day 113 and then every 4 weeks until completion of study treatment
Secondary	Time to treatment failure as assessed by the Kaplan-Meier method at completion of study treatment
Secondary	Progression-free survival as assessed by the Kaplan-Meier method at completion of study treatment
Secondary	Toxicity as assessed by the Kaplan-Meier method and NCI-CTCAE version 3.0 during treatment until 30 days after completion of study treatment